AAAAAA

   
Results: 1-3 |
Results: 3
Epidermal growth factor receptor blockade with C225 plus gemcitabine results in regression of human pancreatic carcinoma growing orthotopically in nude mice by antiangiogenic mechanisms
Authors: Bruns, CJ Harbison, MT Davis, DW Portera, CA Tsan, R McConkey, DJ Evans, DB Abbruzzese, JL Hicklin, DJ Radinsky, R
Citation: Cj. Bruns et al., Epidermal growth factor receptor blockade with C225 plus gemcitabine results in regression of human pancreatic carcinoma growing orthotopically in nude mice by antiangiogenic mechanisms, CLIN CANC R, 6(5), 2000, pp. 1936-1948
Blockade of the epidermal growth factor receptor signaling by a novel tyrosine kinase inhibitor leads to apoptosis of endothelial cells and therapy of human pancreatic carcinoma
Authors: Bruns, CJ Solorzano, CC Harbison, MT Ozawa, S Tsan, R Fan, D Abbruzzese, J Traxler, P Buchdunger, E Radinsky, R Fidler, IJ
Citation: Cj. Bruns et al., Blockade of the epidermal growth factor receptor signaling by a novel tyrosine kinase inhibitor leads to apoptosis of endothelial cells and therapy of human pancreatic carcinoma, CANCER RES, 60(11), 2000, pp. 2926-2935
Therapy of human pancreatic carcinoma implants by irinotecan and the oral immunomodulator JBT 3002 is associated with enhanced expression of inducible nitric oxide synthase in tumor-infiltrating macrophages
Authors: Bruns, CJ Shinohara, H Harbison, MT Davis, DW Nelkin, G Killion, JJ McConkey, DJ Dong, ZY Fidler, IJ
Citation: Cj. Bruns et al., Therapy of human pancreatic carcinoma implants by irinotecan and the oral immunomodulator JBT 3002 is associated with enhanced expression of inducible nitric oxide synthase in tumor-infiltrating macrophages, CANCER RES, 60(1), 2000, pp. 2-7
Risultati: 1-3 |